3.5.2023

Green Claims Directive calls for verified and specified environmental claims in B2C commercial practices

The European Commission adopted a proposal for a Green Claims Directive on 22 March 2023. This completely new directive is intended to act as special legislation concerning environmental claims. The proposal applies to B2C commercial practices and concerns explicit environmental claims made in a textual form or contained in an environmental label that relate to a product or the trader itself. A claim that a packaging is made using recycled plastic, for example, is an environmental claim. 

In addition to proposing a new Green Claims Directive, the Commission has also proposed amending certain other directives, such as the Directive 2005/29 concerning unfair B2C commercial practices. Through the proposed amendments, the Commission would ban generic environmental claims, such as ‘green’, ‘environmentally friendly’ and ‘ecological’, if a company cannot substantiate them with recognised excellent environmental performance. Directive 2005/29 is intended to act as general legislation that applies to environmental claims, whereas the Green Claims Directive would apply to explicit environmental claims and the substantiating, verifying and communicating thereof.

Substantiation and communication requirements specified and increased

Pursuant to the proposed directive, a maker of environmental claims must carry out an assessment to substantiate such claims. The assessment must include certain components. For example, the company must specify whether the environmental claim is related to the product as a whole or only a part thereof. The company must also substantiate the claim by supporting it with widely recognised scientific evidence. Furthermore, the company must demonstrate that the environmental claim does not concern a regulatory requirement that the product must fulfil in any case.

What’s more, the proposed directive lays down requirements on how environmental claims must be communicated. When making a claim that concerns the future, the company would have to include a time-bound commitment for improvements inside its own operations and value chains. The proposed directive also lays down disclosure obligations, according to which the company would have to communicate to the consumer how the improvements that are subject to the environmental claim are achieved.

Companies that offset their emissions would have to provide consumers with more detailed information on the offsetting, such as information on the nature of the offsets and whether these relate to emissions reductions or removals.

Third-party verification before using environmental claims in commercial communication

The proposed directive states that an independent third party, i.e. a conformity assessment body, must verify the substantiation and communication of an environmental claim. The current task of conformity assessment bodies is to assess the conformity of various devices, for example, so this would mean a major change. It should also be noted that the environmental claim must be verified by the third party before the claim is used in commercial communication.

Another major aspect of the proposed directive is that the research data used for assessing the environmental claim should be reviewed and updated whenever the circumstances so require, in any case within five years from when the data was made public. The updated claims are subject to assessment by the conformity assessment bodies as well.

Financial and other consequences for making unfounded environmental claims

Pursuant to the proposed directive, Member States would be required to lay down effective and proportionate penalties for infringing the directive’s provisions. These penalties could take the form of fines imposed by a supervisory authority. The proposed fines would likely be significant as their goal is to prevent any economic benefits derived from making unfounded environmental claims. Under the proposed directive, a company could also be excluded from access to public funding for up to 12 months as penalty for making environmental claims that infringe on the proposed directive. The proposal would also make it possible to confiscate any revenues gained from products that are the subject of infringing claims.

Under the proposed directive, non-governmental organisations, among others, would have the right to submit complaints concerning infringing claims. Non-governmental organisations with an interest in the environmental marketing of companies are likely to make active use of this opportunity.

Recognise environmental claims and substantiate them with evidence

While the contents of the directive proposals might still change and the national implementation of the directives will take some time, companies should already take action. An important first step is that everyone in the organisation is made aware of what constitutes an environmental claim in marketing or company communications. Companies should also assess how consumers are likely to understand their environmental claims and whether these claims are sufficiently substantiated. It is worth noting that current legislation already requires that companies are able to prove an environmental claim when it is made.

Latest references

We are acting as the lead counsel to Fortum in a cross-border transaction in which Fortum is selling its recycling and waste business. The business is sold to thematic impact investing firm Summa Equity through its portfolio company NG Group. The debt-free purchase price is approximately EUR 800 million. The transaction is subject to authority approval and customary closing conditions. Fortum’s recycling and waste business to be sold comprises municipal and industrial waste management and end-to-end plastics, metals, ash, slag and hazardous waste treatment and recycling services. These businesses are located in Finland, Sweden, Denmark and Norway and currently employ approximately 900 employees.
Case published 18.7.2024
We successfully represented Onses Finland Oy before the Finnish Market Court in an exceptionally extensive dispute concerning alleged trademark infringement and unfair business practice. Our client, Onses Finland Oy, is a Finnish sports drink company and the owner of the sports drink brand ONSE. In the spring of 2023, the Polish beverage company OSHEE Polska Sp. z o.o. filed legal action against our client, alleging that the ONSE trademarks and product packaging infringed the OSHEE trademarks. The plaintiff’s secondary claims concerned alleged slavish imitation of the OSHEE sports drink packaging and exploitation of the reputation of the plaintiff. The plaintiff based its suit on registered trademarks as well as allegedly established and reputed figurative and three-dimensional trademarks. The Market Court rejected all of the plaintiff’s claims. The Market Court held that the marks invoked in the suit were neither established nor marks with a reputation in Finland. As regards the registered trademarks, the Market Court found that there was no likelihood of confusion between the OSHEE and ONSE trademarks. As to the secondary claims, the Market Court held that the sports drink packaging used by the plaintiff was a normal beverage bottle, the design of which was partly determined by functional factors. The Market Court also found that there were several blue sports drinks available on the market and that the plaintiff’s product was not the first blue sports drink on the market. The plaintiff failed to show that its product packaging was original or well-known to the average consumer at the time of the launch of our client’s ONSE sports drink product, and the Market Court thus rejected the claims on slavish imitation and exploitation of reputation. The Market Court ordered the plaintiff to pay all of our client’s legal costs with statutory interest. The judgment (MAO:280/2024) is not final.
Case published 11.6.2024
We acted as the legal and ESG advisor to Mérieux Equity Partners on the acquisition of a majority stake in Labquality through a leveraged buyout by its buyout fund, Mérieux Participations 4. Existing shareholders of Labquality, including Cor Group and the management, will reinvest a portion of their proceeds into the company in connection with the transaction. Headquartered in Helsinki, Finland, Labquality is a Nordic player specialized in EQA, CRO activities and regulatory affairs, with a strong local presence in Central and Eastern Europe. The company provides a comprehensive array of services for the healthcare, medical technology, and pharmaceutical industries. The company, employing over 120 professionals and supported by a network of more than 150 external experts and consultants across its offices in Finland, Germany, and Poland, serves a diverse clientele of over 8,000 customers, including major pharmaceutical companies in over 60 countries. Mérieux Equity Partners (MxEP) is an AMF-accredited management company dedicated to equity investments in the Healthcare and Nutrition sectors. MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. The transaction will enable Labquality to pursue its buy & build strategy in Europe to accelerate its CRO activities while continuing strong and recurring growth in the EQA segment. Labquality will benefit from MxEP’s sector expertise and financial resources to achieve its ambition of becoming a leading European CRO and EQA platform, with fully integrated regulatory consulting capabilities to serve major customers across Europe.
Case published 4.12.2023
We advised Voisin Consulting Life Sciences (VCLS) on the acquisition of MedEngine, a leading medical science agency in the Nordics. MedEngine is a digitally minded, premium service provider for the pharmaceutical industry, built upon extensive academic expertise and years of experience in the industry. Founded in 2014, MedEngine has a strong presence across the Nordic countries with offices in Helsinki (Finland), Copenhagen (Denmark), and Stockholm (Sweden). Founded in 1997, VCLS provides end-to-end HealthTech solutions to support biotechnology, pharmaceutical and MedTech manufacturers throughout their product development. With offices in the US, France, UK, Switzerland, Denmark, Madagascar, India, and China, VCLS serves a broad range of developers and investors in HealthTech.
Case published 7.11.2023